Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DX243 phase 1/2a study in healthy volunteers and patients with mild age-related hearing loss
2023-505778-14-00Phase 2Authorised
- Sponsor
- Dendrogenix
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in presbycusis comparing DX243 with Placebo (2 arms). Planned start Sep 2023; status: authorised.
02
Drugs
DX243
03
Conditions
presbycusis
Beyond the preview
Go deeper on 2023-505778-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505778-14-00.